Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.
Immunology
; 157(3): 210-218, 2019 07.
Article
en En
| MEDLINE
| ID: mdl-31107985
ABSTRACT
Tumour infiltration by regulatory T (Treg) cells contributes to suppression of the anti-tumour immune response, which limits the efficacy of immune-mediated cancer therapies. The phosphoinositide 3-kinase (PI3K) pathway has key roles in mediating the function of many immune cell subsets, including Treg cells. Treg function is context-dependent and depends on input from different cell surface receptors, many of which can activate the PI3K pathway. In this review, we explore how PI3Kδ contributes to signalling through several major immune cell receptors, including the T-cell receptor and co-stimulatory receptors such as CD28 and ICOS, but is antagonized by the immune checkpoint receptors CTLA-4 and PD-1. Understanding how PI3Kδ inhibition affects Treg signalling events will help to inform how best to use PI3Kδ inhibitors in clinical cancer treatment.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Linfocitos Infiltrantes de Tumor
/
Linfocitos T Reguladores
/
Inhibidores de Proteínas Quinasas
/
Inmunoterapia
/
Neoplasias
/
Antineoplásicos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Immunology
Año:
2019
Tipo del documento:
Article
País de afiliación:
Japón